{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:46:27Z","timestamp":1769852787909,"version":"3.49.0"},"reference-count":11,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the long-term use of and adherence to urate-lowering therapy (ULT), serum urate (SU) control, and self-reported flares in participants from a randomized controlled trial of allopurinol dose escalation, in order to achieve target SU concentration (&lt; 0.36 mmol\/L) in people with gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>For surviving study participants, ULT dispensing and SU testing within the preceding 12 months was obtained by medical record review. A phone interview was conducted to determine self-reported flares and adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over a mean follow-up of 6.5 (SD 2.5) years since enrollment, 60 out of 183 (33%) participants had died. Review of the 119 surviving participants showed that 98 (82%) were receiving allopurinol, 5 (4%) were receiving febuxostat, and 10 (8%) were not receiving ULT; for the remaining 6 (5.0%), ULT use could not be determined. In those receiving allopurinol, the mean dose was 28.1 (range \u2212600 to 500) mg\/day lower than at the last study visit; 49% were receiving the same dose, 18% were on a higher dose, and 33% were on a lower dose than at the last study visit. SU values were available for 86 of the 119 (72%) participants; 50 out of 86 (58%) participants had an SU concentration of &lt; 0.36 mmol\/L. Of the 89 participants who participated in the phone interview, 19 (21%) reported a gout flare in the preceding 12 months and 79 (89%) were receiving allopurinol; 71 (90%) of those receiving allopurinol reported 90% or greater adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Most of the surviving participants in the allopurinol dose escalation study had good real-world persistence with allopurinol, remained at target SU, and had a low number of self-reported flares.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220270","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T12:20:53Z","timestamp":1656678053000},"page":"1372-1378","source":"Crossref","is-referenced-by-count":8,"title":["Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout"],"prefix":"10.3899","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-8021","authenticated-orcid":false,"given":"George B.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-4476","authenticated-orcid":false,"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0603-5661","authenticated-orcid":false,"given":"Chris","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Haslett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Drake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-3147","authenticated-orcid":false,"given":"Isabel","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2783-7452","authenticated-orcid":false,"given":"Anne M.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa K.","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"2023010522252616000_49.12.1372.1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10067-014-2783-z","article-title":"Management of gout in general practice--a systematic review","volume":"34","author":"Jeyaruban","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2023010522252616000_49.12.1372.2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/rheumatology\/key155","article-title":"Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD)","volume":"57","author":"Scheepers","year":"2018","journal-title":"Rheumatology"},{"key":"2023010522252616000_49.12.1372.3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1071\/HC15017","article-title":"A qualitative study to explore health professionals\u2019 experience of treating gout: understanding perceived barriers to effective gout management","volume":"8","author":"Humphrey","year":"2016","journal-title":"J Prim Health Care"},{"key":"2023010522252616000_49.12.1372.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210872"},{"key":"2023010522252616000_49.12.1372.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211873"},{"key":"2023010522252616000_49.12.1372.6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"2023010522252616000_49.12.1372.7","doi-asserted-by":"publisher","DOI":"10.1177\/1545109709352884"},{"key":"2023010522252616000_49.12.1372.8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jpsychores.2018.10.010","article-title":"The Intentional Non-Adherence Scale (INAS): initial development and validation","volume":"115","author":"Weinman","year":"2018","journal-title":"J Psychosom Res"},{"key":"2023010522252616000_49.12.1372.9","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1007\/s10067-020-05161-w","article-title":"Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study","volume":"39","author":"Kim","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2023010522252616000_49.12.1372.10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13075-019-1918-7","article-title":"Gout, flares, and allopurinol use: a population-based study","volume":"21","author":"Proudman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023010522252616000_49.12.1372.11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.31128\/AJGP-04-19-4909","article-title":"The challenges of managing gout in primary care: results of a best-practice audit","volume":"48","author":"Stamp","year":"2019","journal-title":"Aust J Gen Pract"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T06:44:30Z","timestamp":1672987470000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":11,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,1]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.3899\/jrheum.220270"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220270","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}